The present disclosure provides pharmaceutically acceptable stable salt forms of 15-lipoxygenase products, such as 15-HETrE lysine salt, compositions comprising same and methods of making and using same.

The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements.

The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements.

The present disclosure provides pharmaceutically acceptable stable salt forms of 15-lipoxygenase products, such as 15-HETrE lysine salt, compositions comprising same and methods of making and using same.

The present invention relates to novel antibacterial compounds, pharmaceutical compositions containing them and their use as antimicrobials.

An azido-containing monomer, a polymer containing monomeric units derived from the azido-containing monomer, and various articles containing a substrate and a coating layer of the polymer positioned on the substrate are provided. The azido groups, which are pendant groups of the polymer, can undergo a click chemistry reaction with an unsaturated compound such as those having a terminal C?CH group, a dibenzocyclooctyne-containing group, an unsaturated bicyclic olefinic group, or an amido group. The click chemistry reaction can be used to covalently attach a fluorescent or bioactive compound to the polymer.

An azido-containing monomer, a polymer containing monomeric units derived from the azido-containing monomer, and various articles containing a substrate and a coating layer of the polymer positioned on the substrate are provided. The azido groups, which are pendant groups of the polymer, can undergo a click chemistry reaction with an unsaturated compound such as those having a terminal C?CH group, a dibenzocyclooctyne-containing group, an unsaturated bicyclic olefinic group, or an amido group. The click chemistry reaction can be used to covalently attach a fluorescent or bioactive compound to the polymer.

A compound having the following structure:

##STR00001##

R.sup.1 is a hydrocarbon group containing at least one aromatic or heteroaromatic ring or fused ring system, wherein the at least one aromatic or heteroaromatic ring or fused ring system is optionally substituted; R.sup.2 and R.sup.3 are independently selected from the group consisting of hydrogen (H), halogen atom, and hydrocarbon groups containing 1-6 carbon atoms and optionally substituted; R.sup.4 and R.sup.5 are independently selected from H, halogen atom, and hydrocarbon groups containing 1-6 carbon atoms and optionally substituted; R.sup.6 is H or a hydrocarbon group containing 1-12 carbon atoms and optionally containing one or more heteroatoms selected from O, N, S, and F; and R.sup.a, R.sup.b, R.sup.c, and R.sup.d are independently selected from H; halogen atom; hydrocarbon groups containing 1-3 carbon atoms; amine groups; amide groups; and (CH.sub.2).sub.pT groups, wherein T is a hydrocarbon group with NH linkage; and pharmaceutically acceptable salts thereof.

A compound having the following structure:

##STR00001##

R.sup.1 is a hydrocarbon group containing at least one aromatic or heteroaromatic ring or fused ring system, wherein the at least one aromatic or heteroaromatic ring or fused ring system is optionally substituted; R.sup.2 and R.sup.3 are independently selected from the group consisting of hydrogen (H), halogen atom, and hydrocarbon groups containing 1-6 carbon atoms and optionally substituted; R.sup.4 and R.sup.5 are independently selected from H, halogen atom, and hydrocarbon groups containing 1-6 carbon atoms and optionally substituted; R.sup.6 is H or a hydrocarbon group containing 1-12 carbon atoms and optionally containing one or more heteroatoms selected from O, N, S, and F; and R.sup.a, R.sup.b, R.sup.c, and R.sup.d are independently selected from H; halogen atom; hydrocarbon groups containing 1-3 carbon atoms; amine groups; amide groups; and (CH.sub.2).sub.pT groups, wherein T is a hydrocarbon group with NH linkage; and pharmaceutically acceptable salts thereof.

The present disclosure provides pharmaceutically acceptable stable salt forms of 15-lipoxygenase products, such as 15-HETrE lysine salt, compositions comprising same and methods of making and using same.